Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments-Reference-Cited by-同舟云学术

Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments

Published:2024-01 Issue: Volume:18 Page:
ISSN:1179-5549
Container-title:Clinical Medicine Insights: Oncology
language:en
Short-container-title:Clin Med Insights Oncol

Author:

Balli Sevinc¹²,Bolek Hatice¹²^ORCID,Ürün Yüksel¹²

Affiliation:

1. Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey

2. Ankara University Cancer Research Institute, Ankara, Turkey

Abstract

Recent progress in adjuvant immunotherapy offers hope for improving disease-free survival in high-risk bladder cancer (BC) and renal cell carcinoma (RCC). This review focuses on key trials such as CheckMate 274 and KEYNOTE-564, which show promising results with nivolumab in BC and pembrolizumab in RCC, including a 30% reduction in progression risk. Pembrolizumab also demonstrated overall survival (OS) benefit in RCC. The review also explores the potential of circulating tumor DNA (ctDNA) as a biomarker for better therapy selection and patient stratification. It emphasizes the need for ongoing research to establish survival benefits and suggests integrating biomarkers and risk stratification to optimize adjuvant immunotherapy in BC and RCC.

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/11795549241257238

Reference63 articles.

1. Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients

2. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy

3. A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMA